DGIdb - DABRAFENIB Drug Record

DABRAFENIB BRAF

Interaction Score: 4.76

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Response Type predicted – resistant

Indication/Tumor Type ovarian cancer

combination therapy AMG 232 + Trametinib + Dabrafenib

PMIDs:
28512244 26392102 26811525 27500726 27659046 27770002 22608338 26732095 27255157 25265492 28891408 24265153 24265154 27080216 27048246 27697975 28784858 28268064 22735384 24885690 27312529 22389471 27797976 25370473 27523909 24265155 25452114 25673644 25265494 23031422 29072975 23020132 29431699 25435907 28078132 28480077 25399551 27283860 24583796 23463675 23621583 25656898 22038996 19773371 23845441 14679157 22180495 21156289 21663470 22356324 12460918 18541894 23406027 21129611 22536370 23470635 23251002 24594804 19018267 22586120 23325582 24388723 19010912 24508103 20857202 19537845 21975775 26678033 22448344 25024077 20350999 24163374 19561230 20619739 19255327 22351686 22048237 23833300 24576830 22997239 19238210 23524406 22281684 19404918 25370471 24570209 23612012 20630094 23489023 21426297 21639808 20413299 23812671 23614898 22649091 22972589 24396464 20368568 19001320 24107445 22241789 26619011 24586605 23918947 21163703 24354346 21594703 15035987 22663011 23549875 21683865 22805292 23934108 25157968 25989278 20818844 22773810 21483012 12460919 22743296 12068308 38 2014 8009 2013 8006 2015 31811016 28947956

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB DoCM COSMIC CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB
DABRAFENIB ATXN1L

Interaction Score: 2.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28178529

Sources:
CIViC
DABRAFENIB RAC1

Interaction Score: 1.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25056119 24265153

Sources:
CIViC
DABRAFENIB EZH2

Interaction Score: 0.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27135738

Sources:
CIViC
DABRAFENIB NF1

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23171796

Sources:
CIViC
DABRAFENIB STAG2

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trametinib + Dabrafenib

Indication/Tumor Type melanoma

Response Type decreased response

PMIDs:
27500726

Sources:
JAX-CKB
DABRAFENIB MAP2K1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dabrafenib + SCH772984

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
24463458 25370473 22389471 24265154 24265153 27312529 25673644

Sources:
JAX-CKB CIViC
DABRAFENIB NRAS

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trametinib + Dabrafenib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
27523909 22389471 25452114

Sources:
JAX-CKB CIViC PharmGKB
DABRAFENIB CDKN2A

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24265155

Sources:
CIViC
DABRAFENIB MAP2K2

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25452114 24265153

Sources:
CIViC
DABRAFENIB HLA-DRB1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023328

Sources:
PharmGKB
DABRAFENIB MITF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24265153

Sources:
CIViC
DABRAFENIB HRAS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DABRAFENIB G6PD

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
DABRAFENIB AKT1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24265155

Sources:
CIViC
DABRAFENIB KRAS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Dabrafenib + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27312529

Sources:
JAX-CKB PharmGKB
DABRAFENIB PIK3CA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dabrafenib + Everolimus + Trametinib

Indication/Tumor Type thyroid carcinoma

Response Type sensitive

PMIDs:
27797976

Sources:
JAX-CKB
DABRAFENIB EGFR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trametinib + Dabrafenib

Indication/Tumor Type colorectal cancer

Response Type resistant

PMIDs:
27312529

Sources:
JAX-CKB
DABRAFENIB TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-263 + CGM097 + Dabrafenib + PF-04217903

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27659046

Sources:
JAX-CKB

Pharmaceutical Developer	GlaxoSmithKline
Source Reported Drug Name(s)	Dabrafenib/GSK2118436
Drug Class	RAF Inhibitor
FDA Approval	Melanoma (with BRAF V600 mutation)
Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

44462760	PubChem Drug ID
Dabrafenib	Drug Trade Name
Dabrafenib	Drug Development Name

Drug Class	RAF Inhibitor
Source Reported Drug Name(s)	Dabrafenib/GSK2118436
Pharmaceutical Developer	GlaxoSmithKline

Drug Class	Kinase Inhibitors
FDA Approval	Melanoma (with BRAF V600 mutation)

Drug Indications	antineoplastic agent
Drug Class	Small molecule
FDA Approval	not approved

Response Type	predicted – resistant
Indication/Tumor Type	ovarian cancer
combination therapy	AMG 232 + Trametinib + Dabrafenib

combination therapy	Trametinib + Dabrafenib
Indication/Tumor Type	melanoma
Response Type	decreased response

combination therapy	Dabrafenib + SCH772984
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	Cetuximab + Dabrafenib + Trametinib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	Dabrafenib + Everolimus + Trametinib
Indication/Tumor Type	thyroid carcinoma
Response Type	sensitive

combination therapy	ABT-263 + CGM097 + Dabrafenib + PF-04217903
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

DABRAFENIB	Primary Drug Name
DABRAFENIB	Drug Generic Name
TAFINLAR	Drug Trade Name

GSK2118436A
DABRAFENIB
TAFINLAR
GSK-2118436A
GSK-2118436
GSK2118436
TAFINLAR®
DRB436
rxcui:1424911
pubchem.compound:44462760
drugbank:08912
chemidplus:1195765-45-7
chembl:CHEMBL2028663

antagonist (inhibitory)
inhibitor (inhibitory)

DABRAFENIB Drug Record

DABRAFENIB chembl:CHEMBL2028663 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Response Type predicted – resistant Indication/Tumor Type ovarian cancer combination therapy AMG 232 + Trametinib + Dabrafenib

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB DoCM COSMIC CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28178529

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25056119 24265153

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27135738

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23171796

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Trametinib + Dabrafenib Indication/Tumor Type melanoma Response Type decreased response

PMIDs: 27500726

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Dabrafenib + SCH772984 Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 24463458 25370473 22389471 24265154 24265153 27312529 25673644

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Trametinib + Dabrafenib Indication/Tumor Type melanoma Response Type sensitive

PMIDs: 27523909 22389471 25452114

Sources: JAX-CKB CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24265155

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25452114 24265153

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023328

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24265153

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24265155

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cetuximab + Dabrafenib + Trametinib Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 27312529

Sources: JAX-CKB PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Dabrafenib + Everolimus + Trametinib Indication/Tumor Type thyroid carcinoma Response Type sensitive

PMIDs: 27797976

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Trametinib + Dabrafenib Indication/Tumor Type colorectal cancer Response Type resistant

PMIDs: 27312529

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy ABT-263 + CGM097 + Dabrafenib + PF-04217903 Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 27659046

Sources: JAX-CKB

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Response Type predicted – resistant

Indication/Tumor Type ovarian cancer

combination therapy AMG 232 + Trametinib + Dabrafenib

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB DoCM COSMIC CIViC CancerCommons MyCancerGenomeClinicalTrial PharmGKB TTD FDA OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
28178529

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
25056119 24265153

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
27135738

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
23171796

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trametinib + Dabrafenib

Indication/Tumor Type melanoma

Response Type decreased response

PMIDs:
27500726

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dabrafenib + SCH772984

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
24463458 25370473 22389471 24265154 24265153 27312529 25673644

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trametinib + Dabrafenib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
27523909 22389471 25452114

Sources:
JAX-CKB CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24265155

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
25452114 24265153

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
27023328

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24265153

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
24265155

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Dabrafenib + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27312529

Sources:
JAX-CKB PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dabrafenib + Everolimus + Trametinib

Indication/Tumor Type thyroid carcinoma

Response Type sensitive

PMIDs:
27797976

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trametinib + Dabrafenib

Indication/Tumor Type colorectal cancer

Response Type resistant

PMIDs:
27312529

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-263 + CGM097 + Dabrafenib + PF-04217903

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
27659046

Sources:
JAX-CKB

Alternate Names:

44462760 PubChem Drug ID

Dabrafenib Drug Trade Name

Dabrafenib Drug Development Name

Drug Info:

Drug Class RAF Inhibitor

Source Reported Drug Name(s) Dabrafenib/GSK2118436

Pharmaceutical Developer GlaxoSmithKline

Alternate Names:

DABRAFENIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

FDA Approval Melanoma (with BRAF V600 mutation)

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Kulkarni D et al., 2016, Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms., Pharmacogenomics

Alternate Names:

DABRAFENIB Primary Drug Name

DABRAFENIB Drug Generic Name

TAFINLAR Drug Trade Name

Alternate Names:

D05ROI TTD Drug ID